New Fusarochromanone Derivatives from the Marine Fungus UBOCC-A-117302.

Two new fusarochromanone derivatives, deacetylfusarochromene () and deacetamidofusarochrom-2',3-diene (), along with the previously reported metabolites fusarochromanone TDP-2 (), fusarochromene (), 2,2-dimethyl-5-amino-6-(2'-ene-4'-hydroxylbutyryl)-4-chromone (), fusarochromanone (), (-)-chrysogine (), and equisetin (), were isolated from the marine fungus UBOCC-A-117302. The structures of the compounds were determined by extensive spectrometric (HRMS) and spectroscopic (1D and 2D NMR) analyses, as well as specific rotation. Among them, and showed inhibition of three protein kinases with IC values ranging from 1.

Case report: Thoracic schwannoma as a diagnostic pitfall in both F-Choline PET/CT and F-FDG PET/CT.

We report increased F-FDG uptake in the right posterior mediastinal region in a 70-year-old woman following the discovery of a mass in the aftermath of a bronchitis episode. We also report increased F-Choline uptake in the right posterior mediastinal region in a 66-year-old man with newly discovered prostate cancer, which may indicate the presence of mediastinal metastases. Both patients had a thoracic MRI showing an intense gadolinium enhancement in the same region, consistent with thoracic schwannomas, which were subsequently proven histologically.

Review on radiomic analysis in F-fluorodeoxyglucose positron emission tomography for prediction of melanoma outcomes.

Over the past decade, several strategies have revolutionized the clinical management of patients with cutaneous melanoma (CM), including immunotherapy and targeted tyrosine kinase inhibitor (TKI)-based therapies. Indeed, immune checkpoint inhibitors (ICIs), alone or in combination, represent the standard of care for patients with advanced disease without an actionable mutation. Notably BRAF combined with MEK inhibitors represent the therapeutic standard for disease disclosing BRAF mutation.

Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon.

Uveal melanoma (UV) is a rare and aggressive melanoma with poor 1-year survival. up to 50% of UV patients develop metastases, mainly to the liver. Here, the authors present a 2-deoxy-2-[F] fluoro-D-glucose positron emission tomography (F-FDG-PET) study of a very rare case of secondarily metastatic UV in an 81-year-old Caucasian with a dramatic response to pembrolizumab associated with serial pseudogression.